Oct 12 (Reuters) - Prometic Life Sciences Inc PLI.TO :
* Prometic's PBI-4050 significantly reduces liver fibrosis in patients with alström syndrome
* Prometic Life Sciences-significant reduction of established liver fibrosis demonstrated in all patients that completed 12 weeks of PBI-4050 treatment
* Prometic Life Sciences Inc - liver enzymes reduced to within normal ranges in all patients that completed 12 weeks of PBI-4050 treatment
* Prometic Life Sciences Inc - alström syndrome clinical program to be expanded to include further sites throughout europe and north america
* Prometic Life Sciences-drug safety monitoring board recommended patient enrolment should continue in co's ongoing alström syndrome phase 2 clinical trial Source text for Eikon: ID:nPn3lg844a Further company coverage: PLI.TO